FDA Biosimilars Guidances Address Immunogenicity Studies, European Bridge Data, Analytics
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency’s first three draft guidances on biosimilar product development describe how to characterize biosimilar and reference products and extrapolate data on one condition of use to another. FDA says interchangeability is difficult to determine now and will require a switching study.
You may also be interested in...
Side Step-Wise Development: Sponsors Aren’t Using FDA’s Preferred Approach To Biosimilars
Rather than conduct most analytical characterization and non-clinical studies first, the hallmark of the US FDA approach, biosimilar sponsors are often initiating clinical trials about the same time.
Side Step-Wise Development: Sponsors Aren’t Using FDA’s Preferred Approach To Biosimilars
Rather than conduct most analytical characterization and non-clinical studies first, the hallmark of the US FDA approach, biosimilar sponsors are often initiating clinical trials about the same time.
Biosimilar Guidances: Broader Populations Permitted; More Immunogenicity Requested
New draft Q&A and three final guidances from FDA offer pros and cons for sponsors of biosimilar applications.